Phase 2 N=14 Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma
Grade IV Glioma · Grade IV Astrocytoma · Glioblastoma Multiforme
Primary: Progression of Disease — 14 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,201 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine
Migraine · Migraine With Aura · Migraine Without Aura
Primary: Percentage of Subjects With Freedom From Migraine Headache Pain at 2 Hours Post Dose — 69; 68; 53 Participants
Phase 2 N=84 Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Acute Biphenotypic Leukemia · Acute Myeloid Leukemia · de Novo Myelodysplastic Syndrome
Primary: Phase 1: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of Mitoxantrone — 18 mg/m^2
Phase 2 N=30 Cannabidiol as a Treatment for AUD Comorbid With PTSD
Alcohol Use Disorder · Post Traumatic Stress Disorder
Primary: Number of Drinks Per Day — 4.4885; 5.3623 drinks/day
N/A N=40 Closure of Mucosal and Submucosal Defects in the Gastrointestinal Tract Using the Novel X-Tack Endoscopic Suturing Device
Polyp of Colon · Fistula
Primary: Time to Closure — 23.3; 18.4 minutes
Phase 2 N=16 Statin Adjunctive Therapy for TB
Tuberculosis
Primary: Safety of Escalating Doses of Pravastatin as Assessed by Number of Adverse Events — 8; 4 AEs Grade 3 or Higher
Phase 2 N=18 A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
Primary: Best Overall Response Rate (ORR) — 0.0 percentage of participants
N/A N=80 Deep Learning Enabled Endovascular Stroke Therapy Screening in Community Hospitals
Acute Ischemic Stroke (AIS)
Primary: Time From Emergency Room Arrival to Initiation of Endovascular Stroke Therapy ("Door-to-groin" Time) — 100; 88 minutes
N/A N=300 Evaluation of Polyurethane Male Condoms
Contraception · Prevention of Sexually Transmitted Infections
Primary: Non Inferiority Analysis of Each of the Experimental Condoms Verses the Control Condom With Respect to Clinical Failure Rates (Combined Breakage and Slippage) as Per ISO…
N/A N=8 The Feasibility of Engage Therapy With Video Support for Homebound Older Adults
Depression
Primary: Acceptability: Client Satisfaction Questionnaire (CSQ) — 10.5 score on a scale
Phase 2 N=54 A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease
Graft vs Host Disease
Primary: Percentage of Participants With Overall Response (OR) — 64.7; 68.8; 57.1 percentage of participants
Phase 2 N=3 Ulipristal Acetate for Use in Early Pregnancy Loss
Missed Abortion · Anembryonic Pregnancy · Non-Viable Pregnancy
Primary: Percentage of Participants Recruited to Study Protocol — 37.5 percentage of participants
Phase 2 N=11 Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Primary: Overall Response Rate (ORR) in Participants Treated at the (Maximum Tolerated Dose) MTD, as Assessed Using International Myeloma Working Group (IMWG) Criteria — 40…
Phase 4 N=32 Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)
Hemophilia A
Primary: FVIII Inhibitor Development by the Nijmegen Bethesda Assay — 0; 0; 0 Participants
Phase 3 N=1,735 Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)
Coronavirus Disease (COVID-19)
Primary: Percentage of Participants Who Were Hospitalized and/or Died Through Day 29 (Primary Pre-specified Analysis) — 1.4; 3.9; 4.1; 5.4 Percentage of Participants — p=0.0012